Kornimate/medical-research-clean huggingface dataset:
improving adherence to statin therapy through a medication management application

Conditions: Atherosclerosis

Summary: interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, mediteo gmbh, heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.

patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy will be recruited during hospital-stay or in the neurovascular outpatient clinic of the neurology department as well as in the department of cardiology and vascular medicine at the university hospital essen. participants will be randomly allocated 1:1 to the intervention or control arm and all will receive a low density lipoprotein-cholesterin (ldl-c) target and a statin-prescription as standard of care. all patients will be asked to take the prescribed statin in the evening and to provide ldl-c values measured by the family physician after 6 and 18 months. additional blood will be collected after 6 and 18 months to control for cardiovascular risk-factors in the study center (ldl-c amongst others). in addition, the intervention group will receive free access to a study version of the medication management app mediteo m+ (mediteo gmbh, heidelberg). installation of the app will be performed on the day of enrolment. after entering the medication, the app will remind the patient to take his or her statin therapy according to the therapy plan. each intake has to be confirmed by the patient, either directly via the reminder notification or in the app. in addition, the app can be used to set reminders to go the family physician to take ldl-c values and to document the personal ldl-c values. the endpoint assessment will be performed in blinded manner.

Eligibility criteria:
inclusion criteria: * age \>18 years * atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +/- 10 days of enrolment) * statin naivety * ldl-c \>100 mg/dl. no older than 21 days exclusion criteria: * inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia) * patient has no own smartphone (no device provided for this study) * prior drug therapy to lower ldl-c within the last 30 days * active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \<6 months * use of a digital therapy management application (including mediteo or mediteo m+) within the last month * participation in another interventional trial * pregnancy * inability or unwillingness to provide informed consent

Keywords: smartphone application medication therapy management
the feasibility of petco2 prediction hypotension under spinal anesthesia for cesarean section

Conditions: Hypotension; Carbon Dioxide

Summary: maternal hypotension is a common side effect after spinal anesthesia for cesarean delivery.decreased vascular resistance and cardiac output, due to sympathetic blockade1and blood pooling in blocked areas of the body respectively, are main causes of spinal anaesthesia-induced hypotension during caesarean delivery. cardiac output, which has shown to be a better predictor of organ and placental perfusion than arterial blood pressure.few studies have measured co after spinal anesthesia in the maternal population.this is largely because of the lack of availability of accurate and reproducible noninvasive measurement techniques. up to now, preventing hypotension has continued to focus on arterial blood pressure variables, fluid, and ephedrine requirements as markers of cardiovascular status, because these are more easily measured. investgators hypothesized that co and petco2, in parturients with the degree of hypotension during spinal anaesthesia, would also have a positive and significant association.


Eligibility criteria:
inclusion criteria: * full-term gestation (\>36 and \<41 weeks of gestation) with a singleton pregnancy exclusion criteria: * emergency cases * placenta praevia * preeclampsia * cardiovascular or cerebrovascular disease * morbid obesity with a bmi≥40 * contraindications to spinal anaesthesia
value of sonographic diagnosis of toddler's fracture of the tibia

Conditions: Pediatric Fractures

Summary: this fracture of the distal tibia occurs in 1 to 4 year-old-children. timely diagnosis is important, because it obviates the need for investigations to archive adequate treatment as well as to prevent unnecessary immobilization. the value of sonographic diagnosis of toddler's fracture has been demonstrated. the aim of the present study is to investigate the reliability and accuracy of sonography in the diagnostic workup of the toddler's fracture.

this fracture of the distal tibia occurs in 1 to 4 year-old-children. the child usually presents with an acute onset of limp or refusal to bear weight on one leg. toddlers and young children may present with guarding, but may not have swelling or noticeable deformity. radiologic signs can be subtle too. in some cases initial radiographs is negative and fractures are diagnosed on follow-up studies by periosteal reaction. however, timely diagnosis is important, because it obviates the need for investigations to archive adequate treatment as well as to prevent unnecessary immobilization. the value of sonographic diagnosis of toddler's fracture has been demonstrated. in children it is of particular value as it is comfortable and does not involve the use of ionizing radiation. the aim of the present study is to investigate the reliability and accuracy of sonography in the diagnostic workup of the toddler's fracture.

Eligibility criteria:
inclusion criteria: 1. informed consent 2. suspicion of toddlers fractures exclusion criteria: 1. major delay in treatment

Keywords: sensitivity and sensitivity
the effects of coenzyme a combined with abiraterone on patients with crpc

Conditions: Castration-resistant Prostate Cancer

Summary: the purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme a (coa) with a marketed drug, abiraterone, in chinese patients with castration-resistant prostate cancer (crpc) .

prostate cancer (pca) has developed into the second most common cancer in men. in the united states, pca has the highest morbidity in man. in china, the incidence rate is lower than in europe and the us, but it is growing faster and faster. androgen deprivation therapy (adt) has been the most commonly used treatment for men with advanced prostate cancer for hundreds of years, effective in more than 85 percent of cases, but usually after 20 months or so, half of patients will inevitably develop castration-resistant prostate cancer (crpc), which will become resistant to adt, and patients will relapse. there are several treatments that are trying to address this problem. such as the chemotherapy docetaxel, cabataxel, and the radioactive drug radium 223 dichloride; parp inhibitor olaparib, but the efficacy is limited. for finding some new pathways and targets to treat crpc, a model of pca persister cell was first been established at a cellular level in this study. in light of the new target, we first find a being used clinically drug, coenzyme a (coa), through prescription sieve to treat enzalutamide or abiraterone drug-fast crpc patients. coa functions as an acyl group carrier and assists in transferring fatty acids from the cytoplasm to mitochondria. it is also involved in the oxidation and catabolism of fatty acids. there is an efficient drug action at a cellular level and in animals, and we look forward to it at clinical utility.

Eligibility criteria:
inclusion criteria: - 18-100 years of age combined use with abiraterone or enzalutamide crpc exclusion criteria: - pregnancy acute liver disease or hepatic dysfunction, as determined by levels of alanine aminotransferase (alt) or aspartate aminotransferase levels (ast) more than 2-fold the upper normal limit nephrotic syndrome or serum creatinine (cr) ≥2-fold the upper normal limit and creatine phosphokinase (ck) more than 3-fold the upper normal limit primary hypothyroidism psychiatric patients poorly controlled hypertension, as indicated by a systolic blood pressure \>180 mmhg or diastolic blood pressure \>110 mmhg using contraceptive agent using immunosuppressive drugs, prohibited medication or other non-pca drugs long-term using coa drug
steroid injection for sickle cell arthropathy pain therapy

Conditions: Sickle Cell Disease; Sickle Cell Abnormality

Summary: sickle cell disease (scd) is associated with arthropathy. arthropathy may require periarticular corticosteroid injection therapy. this observational study examines efficacy, and safety of steroid injections in scd patients. data collection includes patient's gender, age, race, smoking history, alcohol intake, analgesic use, pain score, sleep quality, limb joint injections, post-injection analgesia, and post-injection complication. pain is measured using numeric pain scale. sleep quality is measured using likert scale.

sickle cell disease (scd) is associated with arthropathy. arthropathy causes pain which may require periarticular corticosteroid injection therapy. there is inadequate data about the suitability of steroid therapy in scd patients. this prospective observational study examines the efficacy, and safety of periarticular steroid injections in scd patients. this is a cohort study of adult patients undergoing pain management at a pain clinic in canada. data collection includes patient's gender, age, race, smoking history, alcohol intake, analgesic usage, numeric pain score, sleep quality score, limb joint injections, post-injection analgesia, and post-injection complication. pain is measured using numeric pain rating scale. sleep quality is measured using the likert sleep scale. a change in the pain or sleep scores by 2-points is considered significant. data are analyzed with ibm® spss® statistics 25; using student's t-test, anova, pearson chi-square test, and regression analysis. p-value \<0.05 is considered significant.

Eligibility criteria:
inclusion criteria: * adult chronic pain patients * sickle cell disease arthropathy * periarticular steroid injection therapy * regular sleep diary * regular pain diary * informed consent for therapy and diary review exclusion criteria: * pediatric patients * patient without sickle cell disease arthropathy * patient without periarticular steroid injection * irregular sleep diary * irregular pain diary

Keywords: sickle cell
periocline as an adjunct to scaling and root planing for adult periodontitis

Conditions: Adult Periodontitis

Summary: periodontal disease (commonly called gum disease) is generally treated by deep cleaning of the root surfaces of the teeth. this is also called scaling and root planing. placing a topical antibiotic into the periodontal pocket at the time of scaling and root planing may help reduce pocket depth and thus help the periodontal disease. periocline (minocycline hcl) 2.1% gel is a topical antibiotic approved in a number of countries for this use, and is now being tested in the us.


Eligibility criteria:
inclusion criteria: * moderate to severe periodontitis exclusion criteria: * recent periodontal therapy * certain medical or dental conditions * pregnancy * allergy to active drug or related drugs
caresuperb covid-19 antigen test usability

Conditions: COVID-19

Summary: the purpose of this study is to evaluate the usability of the caresuperb covid-19 antigen home test in home use.

covid-19 is a contagious respiratory illness, caused by infection with the novel coronavirus severe acute respiratory syndrome coronavirus 2 (sars-cov-2). this communicable disease is easily transmitted through aerosolized droplets containing the infectious virus. infections with sars-cov-2 can have varying degrees of signs and symptoms, ranging from asymptomatic to severe. individuals infected with sars-cov-2 are believed to be contagious from as early as two days prior to symptom onset to at least ten days after the onset of symptoms. the rapid detection of infections and contacts and the implementation of infection control measures are critical for mitigation of this virus. the caresuperb covid-19 antigen home test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from sars-cov-2 from individuals with or without symptoms or other epidemiological reasons to suspect a covid-19 infection. this kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult lay user-collected anterior nares swab samples from individuals aged 2 to 13 years.

Eligibility criteria:
inclusion criteria: 1. an institutional review board (irb) approved informed consent / assent, if applicable, is signed and dated prior to any study-related activities. 2. male and female subjects 2 years of age and older. 3. subject is willing to provide a self-collected nasal swab sample. (if the subject is under the age of 14, an adult lay-user will collect the sample.) 4. subject agrees to complete all aspects of the study. exclusion criteria: 1. subject has a visual impairment that cannot be restored with glasses or contact lenses. 2. subject has prior medical or laboratory training. 3. subject uses home diagnostics, e.g., glucose meters, hiv tests. 4. subject has prior knowledge of their current covid-19 infection status.
trial of apixaban vs warfarin in reducing rate of cognitive decline, silent cerebral infarcts and cerebral microbleeds in patients with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with apixaban reduces the rate of decline in cognitive function, when compared to warfarin. the investigators also hypothesize that apixaban reduces cognitive decline by reducing the rate of new cerebral infarction and cerebral microbleeds detected by cerebral mri compared to warfarin.


Eligibility criteria:
inclusion criteria: * non-valvular atrial fibrillation * cha2ds2-vasc score \> or = to 2 * never been treated with apixaban (eliquis) or prior treatment of \< 1 month * candidate for oral anticoagulation as assessed by a treating physician exclusion criteria: * valvular atrial fibrillation (rheumatic valve disease,moderate or greater mitral stenosis,mechanical cardiac valve) * active bleeding * prior treatment with apixaban \>1 month * recent stroke within 7 days * dementia * implanted devices not compatible with mri/any cardiac implanted device * claustrophobia * active alcohol/drug abuse * life expectancy \< 1 year * taking asprin with \>100mg doses * known hypersensitivity to warfarin or apixaban * severe renal insufficiency * prior severe bleeding (intracranial bleeding (subdural, subarachnoid, intraparenchymal bleeding),gi bleed requiring transfusion,bleeding from other sites requiring transfusion) * psychosocial reasons that make study participation impractical * currently enrolled in another ind or ide trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints * co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or that could impact the scientific integrity of the study. * prisoners or subjects who are involuntarily incarcerated * subjects who are compulsorily detained for treatment of either psychiatric or physical illness * current or expected systemic treatment with strong dual inhibitors of cyp3a4 and p-gp (any one of rifampin, carbamazepine, phenytoin, st. john's wort, ketoconazole, itraconazole, ritonavir, clarithromycin) * need for dual anti-platelet therapy with aspirin and another agent such as thienopyridine

Keywords: apixaban warfarin
evaluation of urinary exosomes presence from clear cell renal cell carcinoma

Conditions: Clear Cell Renal Cell Carcinoma

Summary: clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. this diagnosis is expensive, invasive and sometimes late. the development of a simple biological test for diagnosis is essential. exosomes are 30 to 150 nm membrane vesicles secreted into the extracellular space by various living cells. these exosomes can be isolated from biological fluids, including urine. the recent study of urinary exosomes is a promising topic for analyzing tumor markers in urine. the investigator's goal is to develop a reliable technique for detecting tumor exosomes in urine in patients with clear cell renal cell carcinoma. the analysis of urinary exosomes could provide a new liquid biopsy tool for the early diagnosis of clear cell renal cell carcinoma.

the primary objective is to detect urinary exosomes, by electron microscopy technique, from clear cell renal cell carcinoma due to exosome markers (cd9) and clear cell kidney cancer (ca9).

Eligibility criteria:
inclusion criteria: patients: * all patients with renal mass requiring surgery (partial or total nephrectomy) * social security affiliation * signed informed consent control : * unscheduled nephrectomy * social security affiliation * signed informed consent exclusion criteria: * insufficient volume of urine sample (\< 100 ml) * patients with a urinary catheter * patients under court-ordered guardianship or curators

Keywords: clear cell renal cell carcinoma urinary exosomes detection electron microscopy technique flow cytometry rt-qpcr
masticatory muscles electromyography in post-pubertal females with forward head posture and temporomandibular disorders

Conditions: Head Pain; TMJ Disorder

Summary: the aim of this study was to evaluate masticatory muscle electrical activity in post-pubertal females with forward head posture (fhp) and temporomandibular disorders (tmd) as well as in post-pubertal females with neutral head posture and with no temporomandibular disorders.

it has been demonstrated by a previous study that a strong relationship exists between forward head posture and temporomandibular disorders and that individuals with forward head posture and temporomandibular disorders exhibit alterations in masticatory muscle electromyographic activity either as a result of the disorder itself or due to a compensatory mechanism associated with the symptoms of temporomandibular disorders . as a consequence, the aim of the study was to evaluate the electromyographic activity of the masticatory muscles in post-pubertal females with forward head posture and temporomandibular disorders as well as in post-pubertal females with neutral head posture and with no temporomandibular disorders.

Eligibility criteria:
inclusion criteria: * age ranging from 17 to 22 years. * body mass index ranging from 18 to 25 kg/m2. * having a normal menstrual cycle. * spending four to six hours per day with bad posture on computer, laptop or smart phones. * fully dentate subjects. exclusion criteria: * having dental loss, acquired dental anomalies, current use of dental prostheses, malocclusion, sleep bruxism. * having inflammatory diseases of the face or jaw, fibromyalgia, or any fractures or surgeries in the orofacial or neck areas.

Keywords: forward head posture temporomandibular disorders masticatory muscles electromyography post-pubertal females
relvar® 100 ellipta® special drug use investigation (copd, long-term)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study aims to investigate the long-term safety and efficacy of relvar® 100 ellipta® (hereinafter referred to as "relvar") in daily clinical practice in subjects with chronic obstructive pulmonary disease (copd), who are naive to relvar. a total of 1000 subjects, from approximately 200 medical institutions, will be registered for this study and 332 of them will be considered for safety analysis. in the investigation, subject registration and data collection will be conducted using an electronic data capture (edc) system. post-registration, the investigator will monitor the information regarding the safety and efficacy of relvar for one year from the start date of treatment with relvar. pneumonia, systemic effects caused by corticosteroids and cardiovascular events will be considered as the priority investigation matters. at the end of observation period, the investigator will enter the obtained information into the edc system and submit it. relvar 100 ellipta is the registered trademark of glaxosmithkline (gsk) group of companies.


Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of copd (bronchitis chronic/emphysema) and who are naive to relvar will be included. exclusion criteria: * among subjects with concomitant asthma, subjects with experience of taking relvar for treatment of asthma will be excluded from the investigation.

Keywords: post-marketing chronic obstructive pulmonary disease drug use investigation relvar 100 ellipta
investigating the effect of dronabinol on post-surgical pain

Conditions: Knee Replacement; Arthropathy of Knee

Summary: this study is designed to investigate the effect of dronabinol on post operative pain in patients undergoing total knee replacement (for their own clinical care).

total knee replacement is a common surgical procedure that restores function to the damaged joint. recovery from this procedure takes weeks and requires opioids to manage post-surgical pain. the goal of this study is to investigate whether dronabinol (synthetic thc) can reduce pain and the need for opioid medication following this particular surgery. subjects will be recruited from the department of orthopedic surgery. all subjects will undergo total knee replacement as part of their clinical care (the surgery itself is not part of this study). the study begins following discharge from the hospital. they will be asked to take dronabinol or placebo as they recover from surgery. during this time they will be given their usual pain medications at discharge which includes opioids for pain. the opioids are to be taken if the subject is experiencing pain. the investigator's hypothesis is that subjects taking dronabinol will need fewer doses of opioids to control pain.

Eligibility criteria:
inclusion criteria: * participants undergoing total knee arthroplasty (tka) at the cuimc department of orthopedic surgery as part of their clinical care. * able to give informed consent and comply with study procedures in english exclusion criteria: * meet dsm-v criteria for current major psychiatric illness, such as bipolar disorder, major depression, or psychosis. subjects with a current substance use disorder will be excluded. subjects with a past cannabis use disorder are excluded. * diagnosis of a major medical or neurological disorder, including orthostatic hypertension, cardiovascular disease (congestive heart failure, unstable angina, or a history of cardiac infarction), hypotension, or neurodegenerative disorders. * subjects taking medications that can lead to a drug interaction.
study of irinotecan hydrochloride (campto(r)) and cisplatin versus etoposide and cisplatin in small cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: to compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed extensive disease-small cell lung cancer (ed-sclc).


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven small cell lung cancer (sclc) * who performance status : 0, 1 exclusion criteria: * no previous radiotherapy is allowed except on bone metastases when newly diagnosed. radiotherapy is not allowed for vena cava syndrome, a stent is recommended ; * no prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).